Compare ARDX & UVV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | UVV |
|---|---|---|
| Founded | 2007 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Farming/Seeds/Milling |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2014 | N/A |
| Metric | ARDX | UVV |
|---|---|---|
| Price | $5.80 | $52.77 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $10.65 | N/A |
| AVG Volume (30 Days) | ★ 2.7M | 164.3K |
| Earning Date | 10-30-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 6.21% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.44 |
| Revenue | $398,234,000.00 | ★ $2,987,411,000.00 |
| Revenue This Year | $22.71 | $3.21 |
| Revenue Next Year | $27.81 | $1.02 |
| P/E Ratio | ★ N/A | $11.90 |
| Revenue Growth | ★ 58.12 | 3.01 |
| 52 Week Low | $3.21 | $49.40 |
| 52 Week High | $6.78 | $67.33 |
| Indicator | ARDX | UVV |
|---|---|---|
| Relative Strength Index (RSI) | 53.23 | 51.30 |
| Support Level | $5.73 | $51.87 |
| Resistance Level | $6.20 | $53.25 |
| Average True Range (ATR) | 0.29 | 0.82 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 57.78 | 66.76 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Universal Corp is an international leaf tobacco supplier. The company procures leaf tobacco from farmers, processes it, and sells it to companies that manufacture consumer tobacco products. Universal does not manufacture or sell any consumer products itself. The company's segments include Tobacco Operations and Ingredients Operations. It generates maximum revenue from the Tobacco Operations segment. Geographically, it derives a majority of revenue from the United States. The company operates in the USA, Belgium, China, Egypt, Philippines, Germany, and Other Countries with majority of revenue from USA.